|
Pronunciation |
|
(mi
noe SYE
kleen) |
|
|
U.S. Brand
Names |
|
Dynacin® Oral; Minocin® IV
Injection; Minocin® Oral; Vectrin® |
|
|
Generic
Available |
|
Yes |
|
|
Canadian Brand
Names |
|
Apo®-Minocycline;
Syn-Minocycline |
|
|
Synonyms |
|
Minocycline Hydrochloride |
|
|
Pharmacological Index |
|
Antibiotic, Tetracycline Derivative |
|
|
Use |
|
Dental: Treatment of periodontitis associated with presence of
Actinobacillus actinomycetemcomitans (AA); as adjunctive therapy in
recurrent aphthous ulcers
Medical: Treatment of susceptible bacterial infections of both gram-negative
and gram-positive organisms; acne, meningococcal carrier state
|
|
|
Pregnancy Risk
Factor |
|
D |
|
|
Contraindications |
|
Hypersensitivity to minocycline, other tetracyclines, or any component;
children <8 years of age |
|
|
Warnings/Precautions |
|
Should be avoided in renal insufficiency, children less than or equal to 8
years of age, pregnant and nursing women; photosensitivity reactions can occur
with minocycline |
|
|
Adverse
Reactions |
|
>10%: Miscellaneous: Discoloration of teeth in children
1% to 10%:
Dermatologic: Photosensitivity
Gastrointestinal: Nausea, diarrhea
<1%: Pericarditis, increased intracranial pressure, bulging fontanels in
infants, dermatologic effects, pruritus, exfoliative dermatitis, rash,
pigmentation of nails, diabetes insipidus syndrome, vomiting, esophagitis,
anorexia, abdominal cramps, paresthesia, acute renal failure, azotemia,
superinfections, anaphylaxis |
|
|
Overdosage/Toxicology |
|
Symptoms of overdose include diabetes insipidus, nausea, anorexia, diarrhea
Following GI decontamination, supportive care only; fluid support may be
required |
|
|
Drug
Interactions |
|
Decreased effect with antacids (aluminum, calcium, zinc, or magnesium),
bismuth salts, sodium bicarbonate, barbiturates, carbamazepine, hydantoins;
decreased effect of oral contraceptives
Increased effect of warfarin |
|
|
Mechanism of
Action |
|
Inhibits bacterial protein synthesis by binding with the 30S and possibly the
50S ribosomal subunit(s) of susceptible bacteria; cell wall synthesis is not
affected |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Well absorbed
Distribution: Crosses placenta; appears in breast milk; majority of a dose
deposits for extended periods in fat
Protein binding: 70% to 75%
Half-life: 15 hours
Elimination: Eventually cleared renally |
|
|
Usual Dosage |
|
Children >8 years: Oral, I.V.: Initial: 4 mg/kg followed by 2 mg/kg/dose
every 12 hours
Adults:
Infection: Oral, I.V.: 200 mg stat, 100 mg every 12 hours not to exceed 400
mg/24 hours
Acne: Oral: 50 mg 1-3 times/day
Hemodialysis: Not dialyzable (0% to 5%) |
|
|
Dietary
Considerations |
|
No data reported |
|
|
Mental Health: Effects
on Mental Status |
|
Reports of memory disturbance, mood stabilizing and antidepressant
effects |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
Barbiturates and carbamazepine may decrease the effects of tetracyclines;
tetracyclines may decrease lithium clearance resulting in an increase in serum
lithium levels and potential lithium toxicity; monitor serum lithium
levels |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
Opportunistic "superinfection" with Candida albicans; tetracyclines
are not recommended for use during pregnancy or in children less than or equal
to 8 years of age since they have been reported to cause enamel hypoplasia and
permanent teeth discoloration. The use of tetracycline's should only be used in
these patients if other agents are contraindicated or alternative antimicrobials
will not eradicate the organism. Long-term use associated with oral
candidiasis. |
|
|
Patient
Information |
|
Take as directed, at regular intervals around-the-clock. May be taken with
food or milk. Complete full course of therapy; do not discontinue even if
condition is resolved. You may experience sensitivity to sun; avoid sun, use
sunblock, or wear protective clothing. Frequent small meals may help reduce
nausea, vomiting or diarrhea. If diabetic, drug may cause false tests with
Clinitest® urine glucose monitoring; use of glucose
oxidase methods (Clinistix®) or serum glucose monitoring
is preferable. Report rash or itching, respiratory difficulty, yellowing of skin
or eyes, change in color of urine or stool, fever or chills, unusual bruising or
bleeding, or unresolved diarrhea. Pregnancy/breast-feeding precautions:
Do not get pregnant while taking this medication - Oral contraceptives
effectiveness may be reduced; use appropriate barrier contraceptive measures.
Breast-feeding is not recommended. |
|
|
Nursing
Implications |
|
Infuse I.V. minocycline over 1 hour |
|
|
Dosage Forms |
|
Capsule:
As hydrochloride: 50 mg, 100 mg
As hydrochloride (Dynacin®,
Vectrin®): 50 mg, 100 mg
Pellet-filled, as hydrochloride (Minocin®): 50 mg, 100
mg
Injection, as hydrochloride (Minocin® IV): 100 mg
Suspension, oral, as hydrochloride (Minocin®)50 mg/5 mL
(60 mL) |
|
|
References |
|
Smilack JD, Wilson WR, and Cockerill FR 3d,
"Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,"
Mayo Clin Proc, 1991, 66(12):1270-80. |
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|